Dysnatraemia in heart failure

European Journal of Heart Failure

Volumn 14, Issue 10, 2012, Pages 1147-1154

  Deubner, Nikolas ^a   Berliner, Dominik ^a   Frey, Anna ^a   Güder, Gülmisal ^a   Brenner, Susanne ^a   Fenske, Wiebke ^a   Allolio, Bruno ^a   Ertl, Georg ^a   Angermann, Christiane E ^a   Störk, Stefan ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Chronic heart failure; Congestive heart failure; Heart failure; Hypernatraemia; Hypervolaemia; Hyponatraemia; Hypovolaemia; Volume regulation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; SODIUM;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERNATREMIA; HYPONATREMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SODIUM BLOOD LEVEL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; HYPERNATREMIA; HYPONATREMIA; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SODIUM; STROKE VOLUME;

EID: 84866691936     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs115     Document Type: Article

References (33)

1. Balling L, Schou M, Videbaek L, Hildebrandt P, Wiggers H, Gustafsson F. Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure. Eur J Heart Fail 2011;13:968-973.
2. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-2460.
3. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67:847-858.
4. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987;10:837-844.
5. Wenzel UO, Hebert LA, Stahl RA, Krenz I. My doctor said I should drink a lot! Recommendations for fluid intake in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:344-346.
6. Cavalcante JL, Khan S, Gheorghiade M. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan. Expert Rev Cardiovasc Ther 2008;6:1331-1338.
7. Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med 2006;73 Suppl 3:S24-S33.
8. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-988.
9. Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, Angermann CE. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail 2008;10:1236-1245.
10. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580.
11. Harrell F, ed. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
12. Aronson D, Verbalis JG, Mueller M, Krum H. Short-and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail 2011;13:327-336.
13. Barsheshet A, Shotan A, Cohen E, Garty M, Goldenberg I, Sandach A, Behar S, Zimlichman E, Lewis BS, Gottlieb S. Predictors of long-term (4-year) mortality in elderly and young patients with acute heart failure. Eur J Heart Fail 2010;12: 833-840.
14. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008;29:339-347.
15. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585.
16. Dzau VJ. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. Am J Kidney Dis 1987;10(1 Suppl 1):74-80.
17. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82: 1724-1729.
18. Goldsmith SR, Francis GS, Levine TB, Cowley AWJr, Cohn JN. Impaired response of plasma vasopressin to orthostatic stress in patients with congestive heart failure. J Am Coll Cardiol 1983;2:1080-1083.
19. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-266.
20. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edemaforming states. Am J Physiol 1988;254:R1017-R1024.
21. Schuster VL, Kokko JP, Jacobson HR. Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest 1984;73: 507-515.
22. Goldsmith SR. Baroreflex loading maneuvers do not suppress increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 1992;19:1180-1184.
23. Riegger AJ. ACE inhibitors in congestive heart failure. Cardiology 1989;76 Suppl 2: 42-49.
24. Swart RM, Hoorn EJ, Betjes MG, Zietse R. Hyponatremia and inflammation: the emerging role of interleukin-6 in osmoregulation. Nephron Physiol 2011;118: 45-51.
25. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R, Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
26. Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 2008;1:2-5.
27. Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, Laupland K. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Crit Care 2008;12:R162.
28. Palevsky PM. Hypernatremia Semin Nephrol 1998;18:20-30.
29. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010;8:793-802.
30. Kinney S, Tibballs J, Johnston L, Duke T. Clinical profile of hospitalized children provided with urgent assistance from a medical emergency team. Pediatrics 2008;121:e1577-e1584.
31. Apte Y, Bellomo R, Warrillow S, Goldsmith D, Gillies M, McGain F. Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion. Crit Care Resusc 2008;10: 306-311.
32. Vazquez R, Bayes-Genis A, Cygankiewicz I, Pascual-Figal D, Grigorian-Shamagian L, Pavon R, Gonzalez-Juanatey JR, Cubero JM, Pastor L, Ordonez-Llanos J, Cinca J, de Luna AB. The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 2009;30:1088-1096.
33. Ghali JK. Hyponatraemia in heart failure: a call for redefinition. Eur Heart J 2007; 28:920-921.